Peptides Similar to NAD+
Compare NAD+ with related peptides and alternatives
📌TL;DR
- •4 similar peptides identified
- •MOTS-c: Both target mitochondrial function and metabolic regulation; MOTS-c is a mitochondria-derived peptide that activates AMPK, which in turn influences NAD+ metabolism via NAMPT upregulation
- •SS-31: Both protect mitochondrial function and are investigated for age-related decline; SS-31 stabilizes cardiolipin in the inner mitochondrial membrane where the electron transport chain (which requires NADH) operates
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| NAD+ (current) | - | - |
| MOTS-c | Both target mitochondrial function and metabolic regulation; MOTS-c is a mitochondria-derived peptide that activates AMPK, which in turn influences NAD+ metabolism via NAMPT upregulation | NAD+ is a ubiquitous coenzyme directly consumed by sirtuins and PARPs; MOTS-c is a signaling peptide encoded by mitochondrial DNA that acts primarily through AMPK activation and nuclear translocation during metabolic stress |
| SS-31 | Both protect mitochondrial function and are investigated for age-related decline; SS-31 stabilizes cardiolipin in the inner mitochondrial membrane where the electron transport chain (which requires NADH) operates | NAD+ is a metabolic coenzyme consumed by hundreds of enzymes across all compartments; SS-31 (elamipretide) is a synthetic tetrapeptide that specifically targets cardiolipin to stabilize mitochondrial cristae structure |
| Epitalon | Both are investigated for anti-aging properties; epitalon activates telomerase while NAD+ supports sirtuin-mediated chromatin maintenance and DNA repair | Epitalon is a synthetic tetrapeptide that primarily acts through telomerase activation and pineal gland regulation; NAD+ acts through a broad metabolic network affecting energy production, DNA repair, and epigenetic regulation |
| Glutathione | Both are critical endogenous molecules that decline with age; glutathione and NAD+ share overlapping roles in redox homeostasis and cellular protection | Glutathione is a tripeptide antioxidant operating primarily through thiol-based redox chemistry and Phase II conjugation; NAD+ is a dinucleotide coenzyme operating through hydride transfer and substrate consumption by sirtuins/PARPs |
MOTS-cBoth target mitochondrial function and metabolic regulation; MOTS-c is a mitochondria-derived peptide that activates AMPK, which in turn influences NAD+ metabolism via NAMPT upregulation
Differences
NAD+ is a ubiquitous coenzyme directly consumed by sirtuins and PARPs; MOTS-c is a signaling peptide encoded by mitochondrial DNA that acts primarily through AMPK activation and nuclear translocation during metabolic stress
SS-31Both protect mitochondrial function and are investigated for age-related decline; SS-31 stabilizes cardiolipin in the inner mitochondrial membrane where the electron transport chain (which requires NADH) operates
Differences
NAD+ is a metabolic coenzyme consumed by hundreds of enzymes across all compartments; SS-31 (elamipretide) is a synthetic tetrapeptide that specifically targets cardiolipin to stabilize mitochondrial cristae structure
EpitalonBoth are investigated for anti-aging properties; epitalon activates telomerase while NAD+ supports sirtuin-mediated chromatin maintenance and DNA repair
Differences
Epitalon is a synthetic tetrapeptide that primarily acts through telomerase activation and pineal gland regulation; NAD+ acts through a broad metabolic network affecting energy production, DNA repair, and epigenetic regulation
GlutathioneBoth are critical endogenous molecules that decline with age; glutathione and NAD+ share overlapping roles in redox homeostasis and cellular protection
Differences
Glutathione is a tripeptide antioxidant operating primarily through thiol-based redox chemistry and Phase II conjugation; NAD+ is a dinucleotide coenzyme operating through hydride transfer and substrate consumption by sirtuins/PARPs
Compounds Related to NAD+#
Several compounds share functional overlap with NAD+ in anti-aging, mitochondrial, and cellular energy research. Below is a detailed comparison of their mechanisms, evidence base, and potential for combination use.
NMN (Nicotinamide Mononucleotide)#
NMN is the direct biosynthetic precursor to NAD+ in the salvage pathway. It is converted to NAD+ by NMNAT enzymes. NMN is the most closely related compound to NAD+ and represents the most direct supplementation strategy for raising intracellular NAD+ levels.
Key differences from direct NAD+ administration:
- NMN is orally bioavailable (absorbed via Slc12a8 transporter and conversion to NR), while NAD+ itself has negligible oral bioavailability.
- NMN supplementation has demonstrated increases in blood NAD+ metabolites in multiple human clinical trials.
- NMN bypasses the rate-limiting NAMPT step of the salvage pathway.
- Cost and availability differ; both NMN and NR are widely available as dietary supplements.
NR (Nicotinamide Riboside)#
NR is another NAD+ precursor that enters the salvage pathway through phosphorylation by NR kinases (NRK1/NRK2) to produce NMN, which is then converted to NAD+. NR has the most extensive human clinical trial data among NAD+ precursors.
Key differences:
- NR requires an additional enzymatic step (NRK-mediated phosphorylation) compared to NMN before reaching NAD+.
- NR has demonstrated reliable dose-dependent NAD+ elevation in multiple placebo-controlled human trials (up to 2000 mg/day).
- NR safety data extend up to 12 weeks in controlled trials.
- Both NR and NMN are converted to nicotinamide (NAM) in the liver, and the effective "boost" to tissue NAD+ may be similar for both precursors.
Niacin (Nicotinic Acid / Vitamin B3)#
Niacin was the original compound identified as preventing pellagra and is the simplest NAD+ precursor, entering through the Preiss-Handler pathway. It remains a relevant alternative for raising NAD+.
Key differences:
- Niacin causes flushing (prostaglandin-mediated vasodilation) at therapeutic doses, limiting tolerability.
- Extended-release niacin has been used clinically for decades for dyslipidemia, with well-established safety data.
- Niacin raises NAD+ but also activates GPR109A (the niacin receptor), producing anti-inflammatory effects independent of NAD+.
- Nicotinamide (niacinamide) is a distinct form of vitamin B3 that enters the salvage pathway directly but inhibits sirtuins at high concentrations.
MOTS-c#
MOTS-c is a mitochondrial-derived peptide encoded by the 12S rRNA gene of mitochondrial DNA. It targets metabolic regulation through AMPK activation and is being investigated for metabolic syndrome and aging.
Combination rationale: MOTS-c and NAD+ act on complementary arms of mitochondrial and metabolic signaling. MOTS-c activates AMPK, which upregulates NAMPT expression and thus supports NAD+ biosynthesis. NAD+ in turn supports the sirtuin and PARP activities that MOTS-c signaling converges upon. No combination studies have been published.
SS-31 (Elamipretide)#
SS-31 is a mitochondria-targeted tetrapeptide that stabilizes cardiolipin in the inner mitochondrial membrane, protecting the structural integrity of the electron transport chain complexes where NADH is oxidized.
Combination rationale: SS-31 protects the downstream machinery (ETC complexes) that utilizes NAD+/NADH for ATP production, while NAD+ supplementation ensures adequate substrate supply. This represents complementary mechanisms at the mitochondrial level, though no formal combination studies exist.
Mechanism Comparison#
| Feature | NAD+ | NMN | NR | MOTS-c | SS-31 | Glutathione |
|---|---|---|---|---|---|---|
| Primary mechanism | Coenzyme/substrate for sirtuins, PARPs, redox reactions | Direct NAD+ precursor (salvage pathway) | NAD+ precursor (via NRK phosphorylation) | AMPK activation, metabolic signaling | Cardiolipin stabilization in mitochondria | Thiol-based antioxidant, Phase II conjugation |
| Oral bioavailability | Very poor | Moderate | Good | Under investigation | Poor (parenteral) | Very poor (intact GSH) |
| Primary route studied | IV, sublingual | Oral | Oral | SC injection (research) | SC/IV injection | IV, oral, topical |
| Human RCT evidence | Limited (IV) | Emerging (multiple trials) | Established (multiple trials) | Phase I/II data | Phase II/III (heart failure) | Small RCTs various indications |
| Targets mitochondria | Yes (via NADH/ETC) | Yes (via NAD+) | Yes (via NAD+) | Yes (AMPK-dependent) | Yes (cardiolipin) | Yes (via GPx, Grx) |
| Affects DNA repair | Yes (PARP substrate) | Yes (via NAD+) | Yes (via NAD+) | Indirect | No | Indirect (redox protection) |
Efficacy Comparison#
No head-to-head randomized trials have been conducted comparing NAD+ directly against NMN, NR, MOTS-c, SS-31, or glutathione. Comparisons are limited to indirect evidence from separate studies with different populations and endpoints.
- NR vs NMN: Both reliably raise blood NAD+ metabolites in human trials. No head-to-head trial has been published, and the relative tissue-level effects may depend on NRK vs Slc12a8 expression patterns.
- IV NAD+ vs oral precursors: IV NAD+ produces immediate and substantial plasma NAD+ elevation; oral precursors produce more gradual and sustained effects. Whether the acute spike from IV administration provides greater therapeutic benefit than sustained oral precursor-driven elevation is unknown.
- NAD+ vs SS-31: These target different aspects of mitochondrial function (substrate supply vs membrane stability) and are not directly comparable in mechanism or evidence.
Evidence Gaps#
Direct head-to-head comparison studies between NAD+ and related compounds are absent. Key unresolved questions include:
- Which NAD+ precursor (NMN vs NR vs niacin) most effectively raises tissue NAD+ in specific organs
- Whether IV NAD+ provides therapeutic benefit beyond what oral precursors achieve
- Optimal combination strategies with mitochondrial-targeted peptides
- Long-term comparative safety and efficacy across routes and formulations
Related Reading#
Frequently Asked Questions About NAD+
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer